CSPG4

Across TCGA pan-cancer cohorts, CSPG4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CSPG4 data layer compared with 29 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher CSPG4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CSPG4 expression acts as an unfavorable survival marker.

OV, BRCA, and KICH are the cancer types where CSPG4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.022	0.844	<.001	36	view →
BRCA	OS	Median	All	0.708	0.964	<.001	16	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LUAD	OS	Median	All	0.398	0.682	.014	11	view →
DLBC	OS	Median	All	0.054	0.842	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →
ACC	DFS	Median	All	0.209	0.659	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CSPG4–OV (OS)

Open the OV breakdown →